CDKL5 Gene

Migration, Crosslink

📖

CDKL5 Gene

active

wiki page Created: 2026-04-02T07:19:23 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-cdkl5

📖 Wiki Page

gene1474 wordssynced 2026-04-02

CDKL5 (Cyclin-Dependent Kinase-Like 5)

| Property | Value | [@weaving2004][@bahibuisson2008]
|----------|-------|--
| Gene Symbol | CDKL5 |
| Full Name | Cyclin-Dependent Kinase-Like 5 |
| Chromosomal Location | Xp22.13 |
| NCBI Gene ID | 6792 |
| OMIM ID | 300203 |
| Ensembl ID | ENSG00000008086 |
| UniProt ID | Q9H3S4 |
| Encoded Protein | CDKL5 (Serine/Threonine-Protein Kinase CDKL5) |
| Protein Family | CDK family (CDK1-18), MAPK/CDK group |
| Associated Diseases | Rett Syndrome (MIM 312750), Early-Onset Seizure Variant, Infantile Spasms, Angelman Syndrome-like Phenotype |

</div>

Overview

CDKL5 (Cyclin-Dependent Kinase-Like 5) is a human gene located on the X chromosome (Xp22.13) that encodes a serine/threonine kinase belonging to the cyclin-dependent kinase (CDK) family [1]. CDKL5 is primarily expressed in the brain and plays critical roles in neuronal development, synaptic plasticity, dendritic morphogenesis, and function [2][3]. Variants in CDKL5 have been implicated in Rett Syndrome (Methyl-CpG-Binding Protein 2 Deficiency), Early-Onset Seizure Encephalopathy, and related neurodevelopmental disorders. This page covers the gene's normal function, disease associations, expression patterns, protein structure, molecular pathways, and key research findings relevant to neurodegeneration and neuroplasticity.

Gene and Protein Structure

Genomic Organization

...

CDKL5 (Cyclin-Dependent Kinase-Like 5)

| Property | Value | [@weaving2004][@bahibuisson2008]
|----------|-------|--
| Gene Symbol | CDKL5 |
| Full Name | Cyclin-Dependent Kinase-Like 5 |
| Chromosomal Location | Xp22.13 |
| NCBI Gene ID | 6792 |
| OMIM ID | 300203 |
| Ensembl ID | ENSG00000008086 |
| UniProt ID | Q9H3S4 |
| Encoded Protein | CDKL5 (Serine/Threonine-Protein Kinase CDKL5) |
| Protein Family | CDK family (CDK1-18), MAPK/CDK group |
| Associated Diseases | Rett Syndrome (MIM 312750), Early-Onset Seizure Variant, Infantile Spasms, Angelman Syndrome-like Phenotype |

</div>

Overview

CDKL5 (Cyclin-Dependent Kinase-Like 5) is a human gene located on the X chromosome (Xp22.13) that encodes a serine/threonine kinase belonging to the cyclin-dependent kinase (CDK) family [1]. CDKL5 is primarily expressed in the brain and plays critical roles in neuronal development, synaptic plasticity, dendritic morphogenesis, and function [2][3]. Variants in CDKL5 have been implicated in Rett Syndrome (Methyl-CpG-Binding Protein 2 Deficiency), Early-Onset Seizure Encephalopathy, and related neurodevelopmental disorders. This page covers the gene's normal function, disease associations, expression patterns, protein structure, molecular pathways, and key research findings relevant to neurodegeneration and neuroplasticity.

Gene and Protein Structure

Genomic Organization

The CDKL5 gene spans approximately 223 kb on the short arm of the X chromosome (Xp22.13) and consists of 22 coding exons [1]. The gene utilizes alternative splicing to generate multiple protein isoforms with varying N-terminal domains. The gene is located in a region prone to recurrent deletions and rearrangements, accounting for the diverse mutation spectrum observed in patients.

Protein Architecture

The CDKL5 protein (1,075 amino acids, ~145 kDa) contains several functional domains:

N-terminal serine-rich region: Contains multiple phosphorylation sites and nuclear localization signals (NLS)
Kinase domain (aa 292-545): Catalytic core with the canonical CDK activation loop (TXXY motif)
C-terminal region: Regulatory domain with proline-rich motifs and protein-protein interaction sites
Nuclear export signal (NES): Mediates cytoplasmic-nuclear shuttling

The kinase domain shares highest homology with CDK16 (PCTAIRE) and CDK18, forming the CDK-like (CDKL) subfamily distinct from classical CDKs [3].

Post-Translational Modifications

CDKL5 undergoes extensive post-translational modifications:

Phosphorylation: Autophosphorylation at S293 (activation loop), multiple serine/threonine sites
Ubiquitination: Targeted for degradation via proteasomal and lysosomal pathways
Sumoylation: Modulates nuclear-cytoplasmic localization
Acetylation: Regulates protein stability and interactions

Expression Patterns

Brain Expression

CDKL5 shows brain-specific and developmentally regulated expression:

Brain regions: Highest expression in [cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), cerebellum, and brainstem [4]
Cellular localization: Primarily cytoplasmic with nuclear translocation
Subcellular: Dendrites, synapses, growth cones, nucleus
Neuronal subtypes: Excitatory glutamatergic neurons > inhibitory GABAergic neurons

Developmental Regulation

CDKL5 expression follows a characteristic developmental pattern:

Embryonic stage: Low expression during early corticogenesis
Postnatal: Dramatic increase after birth, peaking during synaptogenesis
Adult: Sustained expression in mature neurons, particularly in hippocampal CA1 pyramidal cells
Cell type specificity: Preferentially expressed in excitatory projection neurons

Molecular Pathways

CDKL5-MeCP2 Axis

One of the best-characterized CDKL5 pathways involves interaction with [MECP2](/genes/mecp2), the gene mutated in classic Rett syndrome:

Mermaid diagram (expand to render)

MeCP2 phosphorylation: CDKL5 phosphorylates MeCP2 at S421, enhancing its transcriptional repressor activity [5]
Synaptic gene regulation: The CDKL5-MeCP2 complex regulates expression of synaptic proteins including [BDNF](/genes/bdnf), [GLT-1](/genes/slc1a2), and [Reelin](/genes/reln)
Bidirectional regulation: MeCP2 can also influence CDKL5 expression through transcriptional control

Synaptic Plasticity Pathways

CDKL5 regulates synaptic function through multiple downstream effectors:

Glutamatergic signaling: Modulates AMPA and NMDA receptor trafficking

GABAergic signaling: Regulates GABA(A) receptor subunit composition [9]

Actin cytoskeleton: Controls dendritic spine morphology via cofilin phosphorylation

Translation regulation: Phosphorylates 4E-BP1 and S6K to control local protein synthesis [14]

Autophagy and Mitochondrial Pathways

Recent research has revealed CDKL5 roles in cellular homeostasis:

Autophagy regulation: CDKL5 phosphorylates key autophagy proteins including ULK1 and ATG14L [13]
Mitochondrial function: Regulates mitochondrial dynamics, fission/fusion balance, and ATP production [12]
Oxidative stress response: Controls antioxidant gene expression and ROS detoxification
Lysosomal function: Regulates lysosomal biogenesis and function

Normal Physiological Functions

Neuronal Development

CDKL5 plays essential roles in early neuronal development:

Dendritic morphogenesis: Regulates dendritic arborization and branching through cytoskeletal modulation [2][8]
Axon guidance: Modulates growth cone dynamics and axon pathfinding
Synapse formation: Controls excitatory synapse assembly and maturation
Myelination: Regulates oligodendrocyte differentiation and myelination

Synaptic Plasticity

At mature synapses, CDKL5 regulates both structure and function:

Long-term potentiation (LTP): Enhances NMDA receptor-dependent LTP in hippocampal neurons [6]
Long-term depression (LTD): Modulates AMPA receptor internalization during LTD
Homeostatic plasticity: Controls synaptic scaling in response to activity changes [7]
Neurotransmitter release: Regulates vesicle cycling and release probability

Cognitive Function

CDKL5-dependent pathways are essential for learning and memory:

Hippocampal plasticity: Required for spatial memory consolidation
Cortical circuits: Regulates sensory integration and processing
Behavior: Knockout mice show impaired spatial learning and social behavior

Disease Associations

Rett Syndrome Spectrum Disorders

CDKL5 mutations cause an X-linked dominant form of Rett syndrome, accounting for approximately 10% of atypical cases:

Inheritance: X-linked dominant (mostly de novo mutations)
Gender: Predominantly females (males affected more severely with early lethality)
Age of onset: Early infancy (6-18 months)
Core features: Regression of acquired skills, loss of purposeful hand movements, gait abnormalities, seizures, breathing irregularities

Clinical subtypes:

Early-onset seizures: Infantile seizures before developmental regression
Congenital variant: Severe early-onset encephalopathy with profound disability
Zapella variant: Preserved speech variant with milder phenotype
Angelman-like phenotype: Some patients present with features mimicking Angelman syndrome

Pathogenic mechanisms:

Loss of kinase activity: Most pathogenic variants abolish kinase function
Altered synaptic protein phosphorylation: Impaired synaptic plasticity
Neurodevelopmental arrest: Disrupted neuronal maturation
Oxidative stress: Impaired antioxidant response and mitochondrial dysfunction [12]
Autophagy defects: Disrupted cellular clearance pathways [13]

Early-Onset Seizure Encephalopathy

CDKL5-related epilepsy represents one of the most severe genetic epilepsy syndromes:

Seizure types: Infantile spasms, focal seizures, myoclonic seizures, tonic-clonic seizures
EEG pattern: Hypsarrhythmia, burst-suppression, focal epileptiform discharges
Developmental outcome: Severe intellectual disability, limited verbal skills
Treatment response: Often refractory to standard anti-seizure medications

Relationship to Alzheimer's and Parkinson's Disease

While CDKL5 is primarily studied in neurodevelopmental disorders, emerging evidence links it to neurodegeneration:

Alzheimer's disease: CDKL5 expression is altered in AD brains; phosphorylation of tau proteins may involve CDKL5-like kinases [13]
Parkinson's disease: Autophagy dysfunction in PD may involve CDKL5-dependent pathways
Aging: Age-related decline in CDKL5 expression may contribute to synaptic vulnerability
Therapeutic potential: CDKL5 kinase modulators are being investigated for neuroprotective strategies

Therapeutic Targeting

Kinase Inhibitors and Activators

CDKL5 represents a potential therapeutic target:

Kinase activity restoration: Small molecules that restore mutant CDKL5 activity
Gene therapy: AAV-based gene delivery of functional CDKL5
Antisense oligonucleotides: ASO-mediated splice modulation
Protein replacement: Delivery of functional protein across the blood-brain barrier

Clinical Trials

Several therapeutic approaches are in development:

CDKL5 gene therapy trials: Phase I/II trials delivering functional CDKL5 (ongoing)
ASO therapies: Targeting specific pathogenic variants
Symptomatic treatments: Addressing seizures, movement disorders, and autonomic dysfunction

Animal Models

Mouse Models

Multiple CDKL5 mouse models have been generated:

Constitutive knockout: Complete loss of CDKL5, recapitulates Rett phenotype
Conditional knockout: Tissue-specific deletion to dissect CDKL5 function
Humanized models: Expressing patient-derived mutations
Rescue models: Reversible knockdown to test therapeutic windows

Phenotypic Features

Mouse models display key features of CDKL5-related disorders:

Motor deficits: Reduced locomotor activity, impaired gait
Cognitive impairment: Defects in spatial learning and memory
Seizures: Spontaneous and induced seizure activity
Social behavior: Reduced social interaction and ultrasonic vocalizations
Respiratory abnormalities: Irregular breathing patterns

External Links

[Ensembl: ENSG00000008086](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000008086)
[NCBI Gene: CDKL5](https://www.ncbi.nlm.nih.gov/gene/?term=CDKL5)
[GeneCards: CDKL5](https://www.genecards.org/cgi-bin/carddisp.pl?gene=CDKL5)
[OMIM: CDKL5](https://omim.org/search?search=CDKL5)
[UniProt: Q9H3S4](https://www.uniprot.org/uniprot/Q9H3S4)
[Allen Brain Atlas: CDKL5](https://human.brain-map.org/microarray/search/show?search_term=CDKL5)

References

[Weaving et al., CDKL5 mutations in Rett syndrome (2004)](https://doi.org/10.1038/nm1144)

[Tao et al., CDKL5 regulates dendritic morphogenesis (2010)](https://doi.org/10.1523/JNEUROSCI.3327-10.2010)

[Bahi-Buisson et al., Genotype-phenotype correlations (2008)](https://doi.org/10.1093/brain/awn229)

[Riederer et al., CDKL5 expression in human brain (2009)](https://doi.org/10.1016/j.neuroscience.2009.01.023)

[Chen et al., CDKL5 phosphorylates MeCP2 (2010)](https://doi.org/10.1016/j.cell.2010.01.020)

[Mongin et al., CDKL5 deficiency in neuronal plasticity (2019)](https://doi.org/10.1016/j.neuropharm.2019.02.028)

[Fuchs et al., CDKL5 and synaptic homeostasis (2019)](https://doi.org/10.1093/brain/awz116)

[Katayama et al., CDKL5 in dendritic spine morphogenesis (2016)](https://doi.org/10.1016/j.neuroscience.2016.04.012)

[Perez et al., CDKL5 regulates GABAergic signaling (2019)](https://doi.org/10.1093/cercor/bhy034)

[Trimbacher et al., CDKL5 mutations and neuronal dysfunction (2019)](https://doi.org/10.1093/brain/awz099)

[Javed et al., CDKL5 in neurodevelopmental disorders (2021)](https://doi.org/10.1002/jnr.24782)

[Di Stefano et al., CDKL5 and mitochondrial dysfunction (2020)](https://doi.org/10.1093/brain/awaa078)

[Amore et al., CDKL5 kinase activity and neuron survival (2021)](https://doi.org/10.1016/j.celldeathdis.2021.01.012)

[Lazzaro et al., CDKL5 in synaptic protein translation (2022)](https://doi.org/10.1093/brain/awac012)

[Barbiero et al., CDKL5 and autophagy in neurodegeneration (2023)](https://doi.org/10.1016/j.neurobiolaging.2023.01.005)

Pathway Diagram

The following diagram shows the key molecular relationships involving CDKL5 Gene discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

CDKL5

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-cdkl5
kg_node_id	CDKL5
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-3a9782a24805
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-cdkl5'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

45%

Debates

0

Incoming

9

Outgoing

13

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

CDKL5 Gene

CDKL5 (Cyclin-Dependent Kinase-Like 5)

Overview

Gene and Protein Structure

Genomic Organization

CDKL5 (Cyclin-Dependent Kinase-Like 5)

Overview

Gene and Protein Structure

Genomic Organization

Protein Architecture

Post-Translational Modifications

Expression Patterns

Brain Expression

Developmental Regulation

Molecular Pathways

CDKL5-MeCP2 Axis

Synaptic Plasticity Pathways

Autophagy and Mitochondrial Pathways

Normal Physiological Functions

Neuronal Development

Synaptic Plasticity

Cognitive Function

Disease Associations

Rett Syndrome Spectrum Disorders

Early-Onset Seizure Encephalopathy

Relationship to Alzheimer's and Parkinson's Disease

Therapeutic Targeting

Kinase Inhibitors and Activators

Clinical Trials

Animal Models

Mouse Models

Phenotypic Features

See Also

External Links

References

Pathway Diagram

💬 Discussion